Premium
Prognostic of DNA‐synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1–T2, N0–N1, M0 breast cancers: A retrospective multicenter study
Author(s) -
Romain Sylvie,
Spyratos Frédérique,
Descotes Françoise,
Daver Alain,
RostaingPuissant Béatrice,
Bougnoux Philippe,
Colonna Marc,
Bolla Michel,
Martin PierreMarie
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/1097-0215(20000915)87:6<860::aid-ijc16>3.0.co;2-y
Subject(s) - thymidylate synthase , thymidine kinase , enzyme , thymidine , cancer research , dna , medicine , chemistry , oncology , biology , biochemistry , chemotherapy , genetics , fluorouracil , virus , herpes simplex virus
Among the methodological approaches of tumor proliferation, thymidine kinase (TK) and thymidylate synthase (TS) assays take into account the specific pathways of pyrimidine synthesis. Studies pointing to a prognostic value of TK and TS in breast cancer involved small numbers of patients. We investigated the prognostic value of these enzymes and their combination in a large retrospective multicenter study. Nine hundred eight T1T2, N0N1, M0 primary breast cancer samples (median follow‐up 68 months) were tested. TK and TS were measured in cytosols by using standardized radioenzymatic methods. Although a positive correlation was obtained between TK and TS ( p <10 −5 ), major discrepancies were observed in some tumors. High levels of both enzymes were associated with large tumor size, histological grade III and steroid receptor‐negative tumors. Univariate analysis showed that TK, TS and their combination were predictive of poor metastasis‐free (MFS) ( p < 10 −4 ; p =0.004; p < 10 −4 ) and disease‐free survival (DFS) ( p < 10 −4 ; p =0.007; p =0.0001). TK was selected as an independent factor for MFS in Cox analysis. It was the only variable selected in node‐negative patients. Subgroups with specific outcomes, with possible therapeutic implications, were identified: a) in node‐negative patients not receiving adjuvant treatment, TK values in the 4th quartile were associated with poor MFS ( p =0.0002) and DFS ( p =0.0005) as compared to the other quartiles; b) in node‐positive patients receiving adjuvant chemotherapy, low levels of both TK and TS were associated with the highest survival rates (MFS: p =0.04; DFS: p =0.03). Int. J. Cancer 87:860–868, 2000. © 2000 Wiley‐Liss, Inc.